| A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes (NCT07765511) | Eli Lilly and Company | 2026-10-01 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes (NCT07668336) | Eli Lilly and Company | 2026-09-01 |
| A Study of LY4226695 in Healthy Participants (NCT07767487) | Eli Lilly and Company | 2026-08-01 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) (NCT07759245) | Eli Lilly and Company | 2026-08-01 |
| A Study of Eloralintide (LY3841136) in Healthy Participants (NCT07701083) | Eli Lilly and Company | 2026-07-01 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight (NCT07738614) | Eli Lilly and Company | 2026-07-01 |
| A Study of LY4178256 in Healthy Participants (NCT07698210) | Eli Lilly and Company | 2026-07-01 |
| A Study of LY4268989 (MORF 057) in Healthy Participants (NCT07707375) | Eli Lilly and Company | 2026-07-01 |
| A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants (NCT07662798) | Eli Lilly and Company | 2026-07-01 |
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting (NCT07613307) | Eli Lilly and Company | 2026-07-01 |
| A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity (NCT07665879) | Eli Lilly and Company | 2026-06-24 |
| A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy (NCT07654972) | Eli Lilly and Company | 2026-06-24 |
| A Study of LY4065967 in Healthy Participants (NCT07607483) | Eli Lilly and Company | 2026-06-03 |
| A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk (NCT07613294) | Eli Lilly and Company | 2026-06-01 |
| A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication (NCT07612267) | Eli Lilly and Company | 2026-06-01 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) (NCT07101328) | Eli Lilly and Company | 2026-05-28 |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). (NCT07602582) | Eli Lilly and Company | 2026-05-22 |
| A Study of LY3439539 in Participants With Alzheimer's Disease (NCT07598370) | Eli Lilly and Company | 2026-05-21 |
| A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (NCT07589595) | Eli Lilly and Company | 2026-05-20 |
| A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (NCT07592572) | Eli Lilly and Company | 2026-05-20 |
| A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (NCT07571174) | Eli Lilly and Company | 2026-05-14 |
| A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) (NCT07571200) | Eli Lilly and Company | 2026-05-14 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (NCT07287098) | Eli Lilly and Company | 2026-05-13 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (NCT07545759) | Eli Lilly and Company | 2026-05-06 |
| A Study of LY4302814 in Healthy Participants (NCT07566338) | Eli Lilly and Company | 2026-05-06 |
| A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (NCT07483073) | Eli Lilly and Company | 2026-05-04 |
| A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease (NCT07483099) | Eli Lilly and Company | 2026-05-04 |
| Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease (NCT07571161) | Eli Lilly and Company | 2026-04-30 |
| A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (NCT07545772) | Eli Lilly and Company | 2026-04-29 |
| A Study of Eltrekibart (LY3041658) in Healthy Participants (NCT07545590) | Eli Lilly and Company | 2026-04-21 |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers (NCT07226843) | Eli Lilly and Company | 2026-04-17 |
| A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) (NCT07533006) | Eli Lilly and Company | 2026-04-14 |
| A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo (NCT07533019) | Eli Lilly and Company | 2026-04-14 |
| A Study of LY4515100 in Participants With Pain Following Third Molar Removal (NCT07511816) | Eli Lilly and Company | 2026-04-01 |
| A Study of [14C]-LY4064809 in Healthy Participants (NCT07519525) | Eli Lilly and Company | 2026-03-27 |
| LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (NCT07415044) | Eli Lilly and Company | 2026-03-26 |
| A Study of Mirikizumab Solution (LY3074828) in Healthy Participants (NCT07446101) | Eli Lilly and Company | 2026-03-24 |
| A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity (NCT07476118) | Eli Lilly and Company | 2026-03-18 |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07218341) | Eli Lilly and Company | 2026-03-09 |
| A Study of Olomorasib (LY3537982) in Healthy Participants (NCT07439250) | Eli Lilly and Company | 2026-03-02 |
| A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease (NCT07485153) | Eli Lilly and Company | 2026-03-01 |
| A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity (NCT07438444) | Eli Lilly and Company | 2026-02-27 |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function (NCT07426380) | Eli Lilly and Company | 2026-02-24 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain (NCT07285018) | Eli Lilly and Company | 2026-02-16 |
| A Study of Brenipatide in Participants With Opioid Use Disorder (NCT07420283) | Eli Lilly and Company | 2026-02-13 |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (NCT07369011) | Eli Lilly and Company | 2026-02-10 |
| A Study of Brenipatide in Adult Participants With Schizophrenia (NCT07410507) | Eli Lilly and Company | 2026-02-10 |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. (NCT07401862) | Eli Lilly and Company | 2026-02-10 |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (NCT07392190) | Eli Lilly and Company | 2026-02-10 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder (NCT07412756) | Eli Lilly and Company | 2026-02-09 |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (NCT07353931) | Eli Lilly and Company | 2026-02-09 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (NCT07321886) | Eli Lilly and Company | 2026-02-06 |
| A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (NCT07222332) | Eli Lilly and Company | 2026-02-05 |
| A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) (NCT07276958) | Eli Lilly and Company | 2026-02-04 |
| A Study of Remternetug (LY3372993) in Healthy Chinese Participants (NCT07346495) | Eli Lilly and Company | 2026-01-31 |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (NCT07357415) | Eli Lilly and Company | 2026-01-24 |
| A Study of LY4515100 in Healthy Participants (NCT07339722) | Eli Lilly and Company | 2026-01-15 |
| A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus (NCT07299084) | Eli Lilly and Company | 2026-01-14 |
| A Study of LY4064809 in Healthy Adult Participants (NCT07339735) | Eli Lilly and Company | 2026-01-12 |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (NCT07222137) | Eli Lilly and Company | 2026-01-12 |
| A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus (NCT07313813) | Eli Lilly and Company | 2025-12-29 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (NCT07174336) | Eli Lilly and Company | 2025-12-22 |
| A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer (NCT07258836) | Eli Lilly and Company | 2025-12-22 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (NCT07282600) | Eli Lilly and Company | 2025-12-15 |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (NCT07218380) | Eli Lilly and Company | 2025-12-12 |
| A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia (NCT07269210) | Eli Lilly and Company | 2025-12-08 |
| A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis (NCT07258849) | Eli Lilly and Company | 2025-12-02 |
| A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease (NCT07254234) | Eli Lilly and Company | 2025-12-01 |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (NCT07241390) | Eli Lilly and Company | 2025-12-01 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (NCT07169851) | Eli Lilly and Company | 2025-11-28 |
| A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) (NCT07286175) | Eli Lilly and Company | 2025-11-24 |
| A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) (NCT07247084) | Eli Lilly and Company | 2025-11-24 |
| A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy (NCT07225556) | Eli Lilly and Company | 2025-11-18 |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (NCT07232719) | Eli Lilly and Company | 2025-11-17 |
| LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (NCT07186101) | Eli Lilly and Company | 2025-11-10 |
| A Study of How the Body Absorbs LY3537031 (NCT07202871) | Eli Lilly and Company | 2025-11-03 |
| A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (NCT07223840) | Eli Lilly and Company | 2025-11-03 |
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (NCT07223593) | Eli Lilly and Company | 2025-10-31 |
| A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity (NCT07232732) | Eli Lilly and Company | 2025-10-27 |
| A Study of LY4064809 in Healthy Adult Chinese Participants (NCT07247357) | Eli Lilly and Company | 2025-10-24 |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma (NCT07219173) | Eli Lilly and Company | 2025-10-22 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (NCT07213804) | Eli Lilly and Company | 2025-10-22 |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (NCT07213791) | Eli Lilly and Company | 2025-10-22 |
| A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment (NCT07165002) | Eli Lilly and Company | 2025-10-20 |
| A Study of Brenipatide in Participants With Alcohol Use Disorder (NCT07219953) | Eli Lilly and Company | 2025-10-16 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (NCT07215559) | Eli Lilly and Company | 2025-10-16 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) (NCT07165028) | Eli Lilly and Company | 2025-10-15 |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (NCT07219966) | Eli Lilly and Company | 2025-10-15 |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (NCT07215312) | Eli Lilly and Company | 2025-10-13 |
| A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (NCT07202884) | Eli Lilly and Company | 2025-09-30 |
| A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment (NCT07165015) | Eli Lilly and Company | 2025-09-18 |
| A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (NCT07124013) | Eli Lilly and Company | 2025-09-16 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (NCT07153471) | Eli Lilly and Company | 2025-09-15 |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (NCT07157774) | Eli Lilly and Company | 2025-09-02 |
| A Study of LY4064912 in Healthy Participants and With Overweight or Obesity (NCT07152002) | Eli Lilly and Company | 2025-08-28 |
| Epidemiology and Biomarker Study in Alzheimer's Disease (NCT07142954) | Eli Lilly and Company | 2025-08-25 |
| A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint (NCT07140744) | Eli Lilly and Company | 2025-08-22 |
| A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (NCT07137689) | Eli Lilly and Company | 2025-08-18 |
| A Study of LY3985863 in Healthy Participants (NCT07030127) | Eli Lilly and Company | 2025-08-11 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers (NCT07162181) | Eli Lilly and Company | 2025-08-07 |